Efficacy and safety of BLV monotherapy for chronic hepatitis delta: posttreatment results through 48 weeks after the end of treatment from an interim analysis of a randomised Phase 3 study MYR301

被引：0

作者：

Aleman, S. ^{[1
]}

Brunetto, M. ^{[2
,3
]}

Blank, A. ^{[4
]}

Andreone, P. ^{[5
]}

Bogomolov, P. ^{[6
]}

Chulanov, V. ^{[7
]}

Mamonova, N. ^{[8
]}

Geyvandova, N. ^{[9
]}

Morozov, V. ^{[10
]}

Sagalova, O. ^{[11
]}

Stepanova, T. ^{[12
]}

Chee, G. M. ^{[13
]}

Mercier, R. C. ^{[13
]}

Lichtman, A. ^{[13
]}

Manuilov, D. ^{[13
]}

Arterburn, S. ^{[13
]}

Lau, A. H. ^{[13
]}

Osinusi, A. ^{[13
]}

Christian-Cox, Flo. ^{[13
]}

Duff, F. ^{[13
]}

zur Wiesch, J. Schulze ^{[14
]}

Cornberg, M. ^{[15
]}

Zeuzem, S. ^{[16
]}

Wedemeyer, H. ^{[15
]}

Lampertico, P. ^{[17
,18
]}

机构：

[1] Karolinska Inst, Karolinska Univ Hosp, Dept Infect Dis, Stockholm, Sweden

[2] Univ Hosp Pisa, Reference Ctr Tuscany Reg Chron Liver Dis & Canc, Hepatol Unit, Pisa, Italy

[3] Univ Pisa, Dept Clin & Expt Med, Pisa, Italy

[4] Heidelberg Univ, Heidelberg Univ Hosp, Med Fac Heidelberg, Internal Med Dept Clin Pharmacol & Pharmacoepidemi, Heidelberg, Germany

[5] Univ Modena & Reggio Emilia, Baggiovara Hosp, Internal Med, Modena, Italy

[6] MF Vladimirsky Moscow Reg Res & Clin Inst, Moscow, Russia

[7] Sechenov Univ, Moscow, Russia

[8] Minist Hlth Russian Federat, FSBI Natl Res Med Ctr Phthisiopulmonol & Infect Di, Moscow, Russia

[9] Stavropol Reg Hosp, Stavropol, Russia

[10] LLC Med Co Hepatolog, Samara, Russia

[11] South Ural State Med Univ, Chelyabinsk, Russia

[12] LLC Clin Modern Med, Moscow, Russia

[13] Gilead Sci Inc, Foster City, CA USA

[14] Univ Hosp Hamburg Eppendorf, Med Microbiol, Hamburg, Germany

[15] Hannover Med Sch, Clin Gastroenterol Hepatol Infect Dis & Endocrinol, Hannover, Germany

[16] Goethe Univ, Univ Hosp, Dept Nucl Med, Frankfurt, Germany

[17] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Div Gastroenterol & Hepatol, Milan, Italy

[18] Univ Milan, CRC A M&A Migliavacca Ctr Liver Dis, Dept Pathophysiol & Transplantat, Milan, Italy

来源：

DIGESTIVE AND LIVER DISEASE | 2025年 / 57卷

关键词：

D O I：

10.1016/j.dld.2025.01.109

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

P-69

引用

页数：2

共 47 条

[1] EFFICACY AND SAFETY OF BLV MONOTHERAPY FOR CHRONIC HEPATITIS DELTA: POST TREATMENT RESULTS THROUGH 48 WEEKS AFTER THE END OF TREATMENT FROM AN INTERIM ANALYSIS OF A RANDOMIZED PHASE 3 STUDY MYR301
Chee, Grace
Aleman, Soo
Brunetto, Maurizia
Blank, Antje
Andreone, Pietro
Bogomolov, Pavel
Chulanov, Vladimir
Mamonova, Nina
Geyvandova, Natalia
Viacheslav, Morozov
Sagalova, Olga
Stepanova, Tatyana
Manuilov, Dmitry
Arterburn, Sarah
Lau, Audrey
Osinusi, Anu
Christian-Cox, Florence
Duff, Frank
Zur Wiesch, Julian Schulze
Cornberg, Markus
Zeuzem, Stefan
Wedemeyer, Heiner
Lampertico, Pietro
HEPATOLOGY, 2024, 80 : S107 - S108
[2] HIGH RATES OF ADHERENCE TO BULEVIRTIDE MONOTHERAPY FOR CHRONIC HEPATITIS DELTA THROUGH 96 WEEKS: RESULTS FROM AN INTERIM ANALYSIS OF THE PHASE 3 STUDY MYR301
Aleman, Soo
Wedemeyer, Heiner
Brunetto, Maurizia R.
Blank, Antje
Andreone, Pietro
Bogomolov, Pavel
Chulanov, Vladimir
Mamonova, Nina
Geyvandova, Natalia
Morozov, Viacheslav
Sagalova, Olga
Stepanova, Tatyana V.
Da, Ben
Manuilov, Dmitry
Chee, Grace
Li, Mingyang
Lau, Audrey H.
zur Wiesch, Julian Schulze
Cornberg, Markus
Zeuzem, Stefan
Lampertico, Pietro
GASTROENTEROLOGY, 2024, 166 (05) : S1603 - S1604
[3] Bulevirtide monotherapy at low and high dose in patients with chronic hepatitis delta: 24 weeks interim data of the phase 3 MYR301 study
Wedemeyer, Heiner
Aleman, Soo
Andreone, Pietro
Blank, Antje
Brunetto, Maurizia
Bogomolov, Pavel
Chulanov, Vladimir
Geyvandova, Natalia
Hilgard, Gudrun
Mamonova, Nina
Merle, Uta
Viacheslav, Morozov
Sagalova, Olga
Stepanova, Tatyana
zur Wiesch, Julian Schulze
Zotov, Sergey
Zeuzem, Stefan
Lampertico, Pietro
JOURNAL OF HEPATOLOGY, 2021, 75 : S294 - S295
[4] Bulevirtide Monotherapy at Low and High Dose in Patients With Chronic Hepatitis Delta: 24-Week Interim Data of the Phase 3 MYR301 Study
Lee, Stacey
Wedemeyer, Heiner
Aleman, Soo
Brunetto, Maurizia
Blank, Antje
Andreone, Pietro
Bogomolov, Pavel
Chulanov, Vladimir
Mamonova, Nina
Geyvandova, Natalia
Morozov, Viacheslav
Sagalova, Olga
Stepanova, Tatyana
Manuilov, Dmitry
Suri, Vithika
An, Qi
Flaherty, John F.
Osinusi, Anu
zur Wiesch, Julian Schulze
Cornberg, Markus
Zeuzem, Stefan
Lampertico, Pietro
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S858 - S859
[5] Bulevirtide monotherapy at low and high doses in patients with chronic hepatitis delta: 24-week interim data of the Phase 3 MYR301 study
Freismuth, A.
Wedemeyer, H.
Aleman, S.
Brunetto, M.
Black, A.
Andreone, P.
Bogomolov, P.
Chulanov, V.
Mamonova, N.
Geyvandova, N.
Morozov, V.
Sagalova, O.
Stepanova, T.
Manuilov, D.
Suri, V.
An, Qi
Flaherty, J. F.
Osinusi, A.
Zur Wiesch, J. Schulze
Cornberg, M.
Zeuzem, S.
Lampertico, P.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2022, 37 : 52 - 53
[6] Efficacy and safety of 144 weeks of bulevirtide 2 mg or 10 mg monotherapy from the ongoing phase 3 study, MYR301
Lampertico, Pietro
Aleman, Soo
Brunetto, Maurizia
Blank, Antje
Andreone, Pietro
Bogomolov, Pavel
Chulanov, Vladimir
Mamonova, Nina
Geyvandova, Natalia
Morozov, Viacheslav
Sagalova, Olga
Stepanova, Tatyana
Chee, Grace M.
Manuilov, Dmitry
Li, Mingyang
Tseng, Steve
Lau, Audrey
Osinusi, Anu
zur Wiesch, Julian Schulze
Cornberg, Markus
Zeuzem, Stefan
Wedemeyer, Heiner
JOURNAL OF HEPATOLOGY, 2024, 80 : S92 - S92
[7] Efficacy and safety of bulevirtide 2 mg or 10 mg monotherapy for chronic hepatitis delta at 96 weeks: Results from an interim analysis of a phase 3 randomized study
Wedemeyer, Heiner
Aleman, Soo
Brunetto, Maurizia
Blank, Antje
Andreone, Pietro
Bogomolov, Pavel
Chulanov, Vladimir
Mamonova, Nina
Geyvandova, Natalia
Morozov, Viacheslav
Sagalova, Olga
Stepanova, Tatyana
Manuilov, Dmitry
Mercier, Renee-Claude
An, Qi
Freismuth, Aurelie
Flaherty, John F.
Osinusi, Anu
Lau, Audrey
Wiesch, Julian Schulze Zur
Cornberg, Markus
Zeuzem, Stefan
Lampertico, Pietro
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2024, 39 : 101 - 102
[8] EFFICACY AND SAFETY AT 96 WEEKS OF BULEVIRTIDE 2 MG OR 10 MG MONOTHERAPY FOR CHRONIC HEPATITIS DELTA: RESULTS FROM AN INTERIM ANALYSIS OF A PHASE 3 RANDOMIZED STUDY
Wedemeyer, Heiner
Aleman, Soo
Brunetto, Maurizia
Blank, Antje
Andreone, Pietro
Bogomolov, Pavel
Chulanov, Vladimir
Mamonova, Nina
Geyvandova, Natalia
Morozov, Viacheslav
Sagalova, Olga
Stepanova, Tatyana
Manuilov, Dmitry
Mercier, Renee-Claude
An, Qi
Flaherty, John
Osinusi, Anu
Lau, Audrey
zur Wiesch, Julian Schulze
Cornberg, Markus
Zeuzem, Stefan
Lampertico, Pietro
GUT, 2023, 72 (SUPPL_3) : A103 - A104
[9] EFFICACY AND SAFETY AT 96 WEEKS OF BULEVIRTIDE 2 MG OR 10 MG MONOTHERAPY FOR CHRONIC HEPATITIS DELTA: RESULTS FROM AN INTERIM ANALYSIS OF A PHASE 3 RANDOMIZED STUDY
Wedemeyer, Heiner
Aleman, Soo
Brunetto, Maurizia
Blank, Antje
Andreone, Pietro
Bogomolov, Pavel
Chulanov, Vladimir
Mamonova, Nina
Geyvandova, Natalia
Morozov, Viacheslav
Sagalova, Olga
Stepanova, Tatyana
Manuilov, Dmitry
Mercier, Renee-Claude
An, Qi
Flaherty, John
Osinusi, Anu
Lau, Audrey
zur Wiesch, Julian Schulze
Cornberg, Markus
Zeuzem, Stefan
Lampertico, Pietro
GUT, 2023, 72 : A103 - A104
[10] EFFICACY AND SAFETY AT 96 WEEKS OF BULEVIRTIDE 2 MG OR 10 MG MONOTHERAPY FOR CHRONIC HEPATITIS DELTA: RESULTS FROM AN INTERIM ANALYSIS OF A PHASE 3 RANDOMIZED STUDY
Wedemeyer, Heiner
Aleman, Soo
Brunetto, Maurizia R.
Blank, Antje
Andreone, Pietro
Bogomolov, Pavel
Chulanov, Vladimir
Mamonova, Nina
Geyvandova, Natalia
Morozov, Viacheslav
Sagalova, Olga
Stepanova, Tatyana V.
Manuilov, Dmitry
Mercier, Renee-Claude
An, Qi
Flaherty, John F.
Osinusi, Anu
Lau, Audrey H.
Wiesch, Julian Schulze zur
Cornberg, Markus
Zeuzem, Stefan
Lampertico, Pietro
GASTROENTEROLOGY, 2024, 166 (05) : S1600 - S1600

← 1 2 3 4 5 →